

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on March 5, 2024.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, March 5, 2024

As at the date of this announcement, the Directors of the Company are:

Executive Directors:

Mr TO Chi Keung, Simon

(Chairman)

Dr Weiguo SU

*(Chief Executive Officer and
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

(Chief Financial Officer)

Non-executive Directors:

Dr Dan ELDAR

Ms Edith SHIH

Ms Ling YANG

Independent Non-executive Directors:

Mr Paul Rutherford CARTER

(Senior Independent Director)

Mr Graeme Allan JACK

Professor MOK Shu Kam, Tony

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 5, 2024: HUTCHMED (China) Limited (“[HUTCHMED](#)”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2023 annual results of HUTCHMED on February 28, 2024, the following awards granted under the Long Term Incentive Plan (“LTIP”) on March 26, 2021 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 4, 2024:-

| <u>Award Holders</u> | <u>Number of American depository shares (“ADS”)</u> |
|---|---|
| Person Discharging Managerial Responsibilities | |
| Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | 93,545 |
| Mr Johnny Cheng (Executive Director and Chief Financial Officer) | 15,141 |
| Total | <u>108,686</u> |

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

(a) Dr Weiguo Su

| 1 Details of the person discharging managerial responsibilities/person closely associated | | | | | |
|--|--|----------|-----------|-----|------------|
| a) Name | Dr Weiguo Su | | | | |
| 2 Reason for the notification | | | | | |
| a) Position/status | Executive Director, Chief Executive Officer and Chief Scientific Officer | | | | |
| b) Initial notification/Amendment | Initial notification | | | | |
| 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) Name | HUTCHMED (China) Limited | | | | |
| b) LEI | 2138006X34YDQ6OBYE79 | | | | |
| 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) Description of the financial instrument, type of instrument | ADS each representing five Ordinary Shares of US\$0.10 | | | | |
| Identification code | ADS ISIN: US44842L1035 | | | | |
| b) Nature of the transaction | Vesting of awards granted on March 26, 2021 under HUTCHMED's LTIP | | | | |
| c) Price(s) and volume(s) | <table border="1" style="width: 100%;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>93,545 ADS</td> </tr> </tbody> </table> | Price(s) | Volume(s) | Nil | 93,545 ADS |
| Price(s) | Volume(s) | | | | |
| Nil | 93,545 ADS | | | | |
| d) Aggregated information — Aggregated volume — Price | N/A | | | | |
| e) Date of the transaction | 2024-03-04 | | | | |
| f) Place of the transaction | Outside a trading venue | | | | |

(b) Mr Johnny Cheng

| 1 | Details of the person discharging managerial responsibilities/person closely associated | | | | | |
|----------|--|---|----------|-----------|-----|------------|
| a) | Name | Mr Johnny Cheng | | | | |
| 2 | Reason for the notification | | | | | |
| a) | Position/status | Executive Director and Chief Financial Officer | | | | |
| b) | Initial notification/Amendment | Initial notification | | | | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | HUTCHMED (China) Limited | | | | |
| b) | LEI | 2138006X34YDQ6OBYE79 | | | | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the financial instrument, type of instrument | ADS each representing five Ordinary Shares of US\$0.10 | | | | |
| | Identification code | ADS ISIN: US44842L1035 | | | | |
| b) | Nature of the transaction | Vesting of awards granted on March 26, 2021 under HUTCHMED's LTIP | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>15,141 ADS</td> </tr> </tbody> </table> | Price(s) | Volume(s) | Nil | 15,141 ADS |
| Price(s) | Volume(s) | | | | | |
| Nil | 15,141 ADS | | | | | |
| d) | Aggregated information — Aggregated volume — Price | N/A | | | | |
| e) | Date of the transaction | 2024-03-04 | | | | |
| f) | Place of the transaction | Outside a trading venue | | | | |

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS**Investor Enquiries**+852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com**Media Enquiries**

Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com

Zhou Yi, Brunswick

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley / Daphne Zhang,
Panmure Gordon

+44 (20) 7886 2500